Attorney Docket No.:

ISPH-0766

Inventors:

Gaarde et al. 10/655,847

Serial No.:

September 5, 2003

Filing Date: Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

Claim 1 (currently amended): An antisense oligonucleotide 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding PPAR-delta, wherein said antisense oligonucleotide specifically hybridizes with said nucleic acid molecule encoding PPAR delta and has a sequence comprising 3EQ ID NO: 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 95 or 96 to nucleobases 2056-2105 of a 5'-UTR of a nucleic acid molecule encoding human PPAR-delta (SEO ID NO:18).

Claim 2 (original): The antisense oligonucleotide of claim 1 which comprises at least one modified internucleoside linkage.

Claim 3 (original): The antisense oligonucleotide of claim 2 wherein the modified internucleoside linkage is a phosphorothicate linkage.

→ PTOBF

Attorney Docket No.: ISPH-0766

Gaarde et al.

Inventors: Serial No.:

10/655,847

Filing Date:

September 5, 2003

Page 3

Claim 4 (original): The antisense oligonucleotide of claim 1 which comprises at least one modified sugar moiety.

Claim 5 (original): The antisense oligonucleotide of claim 4 wherein the modified sugar moiety is a 2'-0-methoxyethyl sugar moiety.

Claim 6 (original): The antisense oligonucleotide of claim 1 which comprises at least one modified nucleobase.

Claim 7 (original): The antisense oligonucleotide of claim 6 wherein the modified nucleobase is a 5-methylcytosine.

Claim 8 (original): The antisense oligonucleotide of claim 1 which is a chimeric oligonucleotide.

Claim 9 (original): A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8nucleobase portion of a preferred target region on a nucleic acid molecule encoding PPAR-delta.

Claim 10 (original): A composition comprising the antisense oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 11 (original): The composition of claim 10 further comprising a colloidal dispersion system.